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Dear Sirs, 65 
Invasive mucormycosis (IM) in patients with acute leukemia and allogeneic stem cell 66 
transplant (allo-SCT)  recipients treated with antifungal monotherapy is associated with high 67 
mortality rates of 44-49% 1-3. Among the available antifungals, amphotericin B (AmB) 68 
formulations and posaconazole demonstrate the most promising in vitro activities against 69 
Mucorales 4,5, and their combination displays synergistic in vitro activity 6,7. However, pre-70 
clinical studies in neutropenic and diabetic ketoacidotic mice with IM reported no improvement 71 
in survival under a combination of posaconazole and liposomal amphotericin B (L-AmB), 72 
compared to L-AmB monotherapy 8,9. To date, these results have not been evaluated 73 
systematically in a clinical setting, given the rarity of IM. Therefore, the value of combining a 74 
lipid formulation of AmB (Lip-AmB) with posaconazole for the treatment of IM remains a matter 75 
under discussion.  76 
Thirty-two patients with proven/probable IM treated with a combination of Lip-AmB and 77 
posaconazole (Lip-AmB+POS) between 2007 and 2012 were identified in two large registries: 78 
SEIFEM (Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne) and Fungiscope 79 
– A Registry for Emerging Fungal Infections. 80 
Clinical characteristics of these patients are summarized in table 1. All patients, but one, 81 
were adults and were affected by hematological malignancies except 3 cases presenting with 82 
severe aplastic anemia. Most IM occurring in AML patients were documented during the first 83 
induction treatment for the underlying disease. At diagnosis, 22 patients (69%) had a 84 
neutrophil count of <0.5x109/l. Within one month prior to diagnosis 12 patients had received 85 
steroids: in 7 cases, all allo-HSCT for the treatment of graft versus host disease, in the 86 
remaining 5 cases for the treatment of the underlying disease. Only 3 patients (9%) were 87 
affected by diabetes mellitus, unrelated to steroid administration.  88 
The diagnosis of IM was proven in 20 cases (63%) and probable in 12 cases (38%). In 89 
about one third of cases (11 cases), the infection was localized in the lower respiratory tract, 90 
while a disseminated infection (≥ 2 non-contiguous sites) was detected in another 35% of 91 
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cases (n=11). Overall, 21 patients (66%) had received antifungal prophylaxis before the onset 92 
of IM for a median duration of 35 days (range 2-109). Only 3 cases received prophylaxis with 93 
agents with anti-Mucorales activity. Among the 22 patients (69%) who were neutropenic at the 94 
onset of IM, 16 (73%) recovered from neutropenia. Thirteen patients (41%) underwent surgical 95 
excision of infected tissue. In the majority of patients (29 cases, 91%) Lip-AmB+POS was 96 
initiated due to lack of response to antifungal monotherapy. In 20 patients (63%) only one line 97 
of monotherapy had been administered for a median time of 18 days (range 13-64) before 98 
initiation of Lip-AmB+POS. In 75% of these cases (n=15), an AmB formulation had been 99 
administered: 12 L-AmB, 2 lipid complex AmB, 1 AmB. In the remaining 5 cases, 100 
posaconazole (2 cases), voriconazole (1 case) and caspofungin (2 case), had been given. In 9 101 
cases (28%) two different lines of treatment had been administered prior to Lip-AmB+POS. 102 
Lip-AmB+POS was administered as first-line treatment to only 3 patients (9%). Among 103 
the 29 patients (91%) receiving Lip-AmB+POS as second or third line therapy, 27 (93%) 104 
received posaconazole as an addition to an ongoing treatment with Lip-AmB. In 28 patients 105 
(88%), posaconazole was administered at 800 mg/d, in 2 patients (6%) at a lower dosage (400 106 
mg/d and 600 mg/d) and in 2 patients (6%) at a higher dosage (1600 mg/d and 3200 mg/d). 107 
Lipid complex AmB was chosen for combination with posaconazole in 5 patients (16%), L-108 
AmB in 27 patients (84%). The standard dosage of L-AmB (3 mg/kg) was used in 10 cases 109 
(32%) and a higher dosage (5 mg/kg or more) in 17 cases (53%). The median duration of 110 
combined treatment was 32 days (3-157 days). In 3 cases (9%), deferasirox was added to Lip-111 
AmB+POS. 112 
In any patients the antifungal treatment was stopped for drug-related toxicities. 113 
Comparing patients that received L-AmB at 3 mg/kg and those who received L-AmB at 5 114 
mg/kg or higher, none of them showed relevant nephrotoxicity. 115 
After a median follow-up of 3 months, clinical improvement of IM was observed in 18 116 
patients (56%): 11 (34%) complete and 7 (22%) partial responses. Stable disease was 117 
demonstrated in 5 patients (16%). Nine patients (28%) did not respond to treatment and died 118 
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of progressive IM. Of the 3 patients (9%) receiving Lip-AmB+POS as front-line therapy, only 2 119 
experienced a complete response, while the third died of IM.  120 
At day 90 after the diagnosis of IM, 19 patients (59%) had died, 9 due to progression of 121 
IM and 10 due to progression of the underlying hematological disease, even though a clinical 122 
improvement of IM was observed in 5 cases. Maintenance treatment with oral posaconazole 123 
had been administered in all 18 responsive cases (56%) for a median of 74 days (10-175 124 
days), without relapse of IM. Thirteen patients (41%) were still alive at least 12 months after 125 
diagnosis of IM and displayed no signs of active infection; 11 of these patients (85%) were 126 
able to continue treatment of the underlying hematological malignacy and 4 (12%) underwent 127 
an allo-SCT without relapse of IM after a time ranging between 9 to 16 months. In a univariate 128 
analysis, allo-SCT and steroid administration were negatively associated with treatment 129 
success. Recovery from neutropenia was identified as a potentially protective factor (table 2). 130 
Due to the low number of cases at multivariate analysis we did not identified any significant 131 
parameter 132 
In the vast majority of our cases, Lip-AmB was used as front-line treatment, and 133 
posaconazole was added when no satisfactory response was observed. Hence, Lip-134 
AmB+POS was prescribed as a salvage approach. In 56% of our cases a favourable clinical 135 
response was achieved (>70% if stable disease was included into the definition). This rate 136 
compares favourably with recent case series, in which response rates ranged from 32% to 137 
59% 1-3, and with the response rates reported from a compassionate use trial that evaluated 138 
posaconazole as salvage therapy. In the latter trial, 6 of 13 patients (46%) receiving Lip-139 
AmB+POS displayed a favourable response; all of which were partial responses 10. 140 
Clearly, many factors besides the choice of antifungal agents may have contributed to 141 
patient outcome. We were not able to evaluate the impact of different Lip-AmB and 142 
posaconazole dosages on patient outcome due to the limited number of cases and the lack of 143 
regular therapeutic drug monitoring. Another important factor we could not adequately control 144 
for is the impact of surgical debridement on patient outcome. In contrast with previous 145 
analyses 3,11, surgical removal of infected tissue was not identified as a protective factor. This 146 
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may, however, be explained by limited sample size and a tendency to perform surgery on 147 
severely ill patients, only. 148 
Finally, the influence of deferasirox could not be assessed in our analysis. While 149 
previous studies in vitro as well as animal studies suggested a synergistic effect of deferasirox 150 
in combination with L-AmB 12, a recent interventional trial on this issue failed to confirm such 151 
an association 13. In our series, deferasirox was added in 3 cases only, all with a favourable 152 
outcome. Nevertheless, this observation should be considered no more than suggestive. 153 
In patients responding to therapy, maintenance treatment with posaconazole was 154 
frequently administered for prolonged periods of time. It permitted 11 patients (34%) to 155 
continue treatment for the underlying malignancy, and prevented relapse of IM during 156 
subsequent periods of neutropenia. Of note, in 6 (19%) of these cases, an allo-SCT could be 157 
performed. 158 
The risk that our series may suffer from a selection bias due to the inclusion of only 159 
those patients that survived long enough to receive a combination therapy it is possible, 160 
however  we wanted to analyze the role of a combination therapy in those patients who have 161 
performed using 2 large registries, in which were collected both patients have a good outcome 162 
than those who have a bad course. 163 
In conclusion our analysis suggests that a combined antifungal treatment with Lip-164 
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    Table 1. Clinical characteristics and risk factors  of 32 patients who developed IM 246 











Underlying disease   
 AML 20  64 
 ALL 3  9 
 Multiple Myeloma 3  9 
 Lymphoma 3  9 
 SAA 3  9 
 
Phase of hematological disease 
  
 Induction AML/ALL 13  41 
 Relapse/ Salvage 4  12 
 Consolidation AML 2  6 
 allo-BMT 8 25 
 Supportive/No Treatment  5  16 
 
Immunosuppressive therapy  
before diagnosis of IM 
  
 Steroids 12 § 37 
 Immunosuppressors (CyA and 
others) 


















Prophylaxis 21  66 
 None 11  34 
 Itraconazole 4  13 
 Posaconazole 2  6 
 Fluconazole 12  38 
 Other# 3  9 
 
Species n % 
 Lichtheimia corymbifera 6 19 
 Cunninghamella bertholletiae 1 3 
 Mucor spp. 10 31 
 Rhizomucor spp. 6 19 
 Rhizopus spp. 9 28 
 
Site of infection   
 Lung only 11 35 
 Rhinocerebral only 5 15 
 Skin only 2  6 
 Other 3 ^ 9 
10 
 
 Multiple  11 35 
 
Lines of therapy prior Lip-AmB+POS   
 0 3 9 
 1 20 63 
 2 9 28 
Lipid formulation in Lip-AmB+POS   







L-AmB dose  
 3 mg/kg 10  37 
 5 mg/kg 14 48 
 >5 mg/kg 3 15 
 
















Treatment response  
 Favorable (CR +PR) 18  56 
 Stable 5  16 
 Deterioration/Failure  9 28 
 
Continuation of therapy with POS 18  56 
 
Outcome at 90 days after diagnosis  
of IM 
 
 Death due to HM 10  31 
 Death due to IM 9 28 
 
Subsequent allo-HSCT 4 12 
 
 247 
Legend: AML: Acute myeloid leukemia; ALL: Acute Lymphoid leukemia; SAA: severe aplastic 248 
anemia; allo-HSCT: allogeneic hemopoietic stem cell transplantation; CyA: cyclosporine A; HC: 249 
hematological condition; L-AmB: liposomal amphotericin B; IM: invasive mucormycosis; POS: 250 
posaconazole  251 
^ 1CNS only, 1 liver and small bowel, 1 soft tissue, * out of 22 patients neutropenic at the onset of 252 
IM 253 
§ 7 patients received both steroids and other immunusuppressants 254 




      Table 2. Univariate analysis of factors influencing treatment success 257 
 258 
 all favourable 
 














































allo HSCT  
 yes 































































     
L-Amb dose 
 3mg/kg 









































Recovery from neutropenia ** 
 yes  













Legend: AML: Acute myeloid leukemia; HC: heamatological condition; SAA: severe aplastic 260 
anemia; allo-HSCT: allogeneic hemopoietic stem cell transplantation; L-AmB: liposomal 261 
amphotericin B; POS: posaconazole. 262 
* out of 22 patients neutropenic at the onset of IM 263 
§ this data coinciding with immunosuppressive therapy 264 
 265 
